Additionally, another retrospective study indicated that prostate-specific membrane antigen (PSMA)-PET showed positivity in 196 out of 200 patients with nmCRPC, revealing pelvic disease in 44% and metastatic disease in 55% of patients despite negative conventional imaging [30]. This evidence concerns the gene FOLH1 and metastatic neoplasm.